ATRC Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

139.29M

+12.08%

-0.053

-33.56%

138.67M

+12.18%

-0.107

-23.47%

152.21M

+11.8%

-0.041

+107.15%

Estimates Revision

The market is revising Upward the revenue expectations for AtriCure, Inc. (ATRC) for FY2025, with the revenue forecasts being adjusted by 0.45% over the past three months. During the same period, the stock price has changed by 13.68%.

Revenue Estimates for FY2025

Revise Upward

+0.45%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-31.27%

In Past 3 Month

Stock Price

Go Up

+13.68%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast ATRC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATRC is 52.60 USD with a low forecast of 45.00 USD and a high forecast of 64.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

45.00

Averages

52.60

High

64.00

Current: 0.000

Low

45.00

Averages

52.60

High

64.00

JPMorgan

NULL -> Overweight

maintain

$42 -> $48

2025-12-16

Reason

JPMorgan

Price Target

$42 -> $48

2025-12-16

maintain

NULL -> Overweight

Reason

JPMorgan raised the firm's price target on AtriCure to $48 from $42 and keeps an Overweight rating on the shares. The firm updated the company's model.

Canaccord

William Plovanic

Buy

maintain

$51 -> $53

2025-07-30

Reason

Canaccord

William Plovanic

Price Target

$51 -> $53

2025-07-30

maintain

Buy

Reason

Canaccord analyst William Plovanic raised the firm's price target on AtriCure to $53 from $51 and keeps a Buy rating on the shares. The firm said they reported a very solid Q2, with strength across the rest of the business more than offsetting further degradation of US EPi-Sense/Hybrid. The target increase reflects comp group multiple expansion and increased expectations.

BTIG

Buy

upgrade

$52 -> $54

2025-07-30

Reason

BTIG

Price Target

$52 -> $54

2025-07-30

upgrade

Buy

Reason

BTIG raised the firm's price target on AtriCure to $54 from $52 and keeps a Buy rating on the shares. The company reported a "wow" quarter, exceeding expectations on the top and bottom as revenue growth accelerated to 16.5%, with results driven by new product launches across the Pain and Appendage Management franchises, the analyst tells investors in a research note.

Citizens Capital Markets

Daniel Stauder

Buy

Reiterates

$60

2025-04-02

Reason

Citizens Capital Markets

Daniel Stauder

Price Target

$60

2025-04-02

Reiterates

Buy

Reason

Canaccord Genuity

William Plovanic

Strong Buy

Maintains

$66 → $52

2025-03-28

Reason

Canaccord Genuity

William Plovanic

Price Target

$66 → $52

2025-03-28

Maintains

Strong Buy

Reason

Canaccord lowered the firm's price target on AtriCure to $52 from $66 and keeps a Buy rating on the shares. The firm updated its model folloing the company's Investor Day that both reiterated its 2025 guidance and provided an aspirational LRP that included three-year objectives as well as targets for 2030.

Needham

Mike Matson

Strong Buy

Reiterates

$51

2025-03-27

Reason

Needham

Mike Matson

Price Target

$51

2025-03-27

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for AtriCure Inc (ATRC.O) is -185.50, compared to its 5-year average forward P/E of -59.61. For a more detailed relative valuation and DCF analysis to assess AtriCure Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-59.61

Current PE

-185.50

Overvalued PE

-28.97

Undervalued PE

-90.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

1287.02

Current EV/EBITDA

29.90

Overvalued EV/EBITDA

8559.23

Undervalued EV/EBITDA

-5985.18

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.82

Current PS

3.36

Overvalued PS

9.08

Undervalued PS

2.55

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 521.1% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 521.1% over the last month.

Sold

Bought

ATRC News & Events

Events Timeline

No data

News

7.5

01-01Businesswire

AtriCure Inc (ATRC) Releases 2025 Product Pipeline Analysis Report

2.0

2025-12-19NASDAQ.COM

AtriCure (ATRC) Sees a 6.32% Increase Over the Past Week: Key Information to Consider

4.0

2025-11-25NASDAQ.COM

Wall Street Analysts Predict AtriCure (ATRC) May Surge 36.3%: Here's How to Invest

People Also Watch

Frequently Asked Questions

What is AtriCure Inc (ATRC) stock price today?

The current price of ATRC is 41.46 USD — it has decreased -2.23 % in the last trading day.

What is AtriCure Inc (ATRC)'s business?

AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.

What is the price predicton of ATRC Stock?

What is AtriCure Inc (ATRC)'s revenue for the last quarter?

AtriCure Inc revenue for the last quarter amounts to 134.27M USD, increased 15.84 % YoY.

What is AtriCure Inc (ATRC)'s earnings per share (EPS) for the last quarter?

AtriCure Inc. EPS for the last quarter amounts to -0.01 USD, decreased -94.12 % YoY.

What changes have occurred in the market's expectations for AtriCure Inc (ATRC)'s fundamentals?

How many employees does AtriCure Inc (ATRC). have?

AtriCure Inc (ATRC) has 1300 emplpoyees as of January 10 2026.

What is AtriCure Inc (ATRC) market cap?

Today ATRC has the market capitalization of 2.06B USD.